Talaris Therapeutics (Talaris Therapeutics) Investments And Advances : $0.00 Mil (As of Jun. 2023)

View and export this data going back to 2021. Start your Free Trial

What is Talaris Therapeutics Investments And Advances?

Talaris Therapeutics's Investments And Advances for the quarter that ended in Jun. 2023 was $0.00 Mil.

Talaris Therapeutics Investments And Advances Historical Data

The historical data trend for Talaris Therapeutics's Investments And Advances can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Talaris Therapeutics Investments And Advances Chart

Talaris Therapeutics Annual Data

Trend

Dec19

Dec20

Dec21

Dec22

Investments And Advances

Talaris Therapeutics Quarterly Data
	Dec19	Mar20	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23
Investments And Advances	Get a 7-Day Free Trial										-	-	-	-	-

Talaris Therapeutics Investments And Advances Calculation

Investments And Advances includes all the non-current investments in affiliates, real estate, securities, etc.

Talaris Therapeutics (Talaris Therapeutics) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Talaris Therapeutics Inc (NAS:TALS) » Definitions » Investments And Advances

Comparable Companies

Traded in Other Exchanges

N/A

Address

93 Worcester Street, Wellesley, MA, USA, 02481

Website

https://www.talaristx.com

Talaris Therapeutics Inc is a late-clinical stage biotechnology company. It is developing transformative cell therapies with the potential to eliminate the burden of chronic immunosuppression for organ transplant recipients as well as induce durable remissions in patients with severe autoimmune and immune-mediated disorders.

Executives

Cariad Chester	director	C/O TOURMALINE BIO, INC., 27 WEST 24TH STREET, SUITE 702, NEW YORK NY 10010
Yung H. Chyung	officer: Chief Medical Officer	C/O SCHOLAR ROCK, 620 MEMORIAL DR., 2ND FLOOR, CAMBRIDGE MA 02139
Caley Castelein	director	THOM. WEISEL HEALTHCARE VENTURES, ONE MONTGOMERY STREET, SAN FRANCISCO CA 94104
W Bradford Middlekauff	officer: CBO, GC and Secretary	200 CONNELL DRIVE, SUITE 1600, BERKELEY HEIGHTS NJ 07922
Aaron Kantoff	director	C/O CENTESSA PHARMACEUTICALS PLC, D. HODGKIN BLDG, BABRAHAM RSRCH CAMPUS, CAMBRIDGE X0 CB22 3FH
Sandeep Chidambar Kulkarni	director, officer: CEO	92 MORNINGSIDE AVE., APT 7E, NEW YORK NM 10027
Kevin Bruce Johnson	officer: Chief Regulatory Officer	C/O TOURMALINE BIO, INC., 27 WEST 24TH STREET, SUITE 702, NEW YORK NY 10010
Ryan F. Robinson	officer: Interim CFO	C/O TOURMALINE BIO, INC., 27 WEST 24TH STREET, SUITE 702, NEW YORK NY 10010
Parvinder Thiara	director	C/O TOURMALINE BIO, INC., 27 WEST 24TH STREET, SUITE 702, NEW YORK NY 10010
Susan Dana Jones	officer: Chief Technology Officer	C/O TOURMALINE BIO, INC., 27 WEST 24TH STREET, SUITE 702, NEW YORK NY 10010
Suzanne Ildstad	director, 10 percent owner, officer: Chief Scientific Officer	C/O TALARIS THERAPEUTICS, INC., 93 WORCESTER STREET, SUITE 120, WELLESLEY MA 02481
Scott Requadt	director, officer: See Remarks	101 MAIN STREET, SUITE 1210, CAMBRIDGE MA 02142
Francois Nader	director	550 HILLS DRIVE, BEDMINSTER NJ 07921
Karen L. Smith	director	C/O JAZZ PHARMACEUTICALS PLC, 5TH FL, WATERLOO EXCHANGE, WATERLOO RD, DUBLIN L2 4 L2
Longitude Capital Partners Iii, Llc	10 percent owner	800 EL CAMINO, SUITE 220, MENLO PARK CA 94025